Welcome!

News Feed Item

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

Summary

Uveitis is a serious eye condition that often results in permanent vision damage due to frequent recurrence even after treatment. It consists of a group of diseases that present with inflammation of the uvea, can occur in one or both eyes, and may also affect the adjacent tissues such as the retina, optic nerve, and vitreous humor. Symptoms may include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. Uveitis has a wide variety of causes such as autoimmune disorders, infectious agents, or toxins; however, the cause is often unknown for a significant proportion of the cases.

In 2012, GlobalData epidemiologists forecast the 6MM had 223,559 incident cases of uveitis, 75% of which (168,264 cases) occurred in the US. Incident cases in the 6MM are expected to increase slightly to 245,353 cases by 2022, at the rate of 0.97% per year. In 2012, the 6MM had 665,778 prevalent cases of uveitis, which will increase to 730,913 cases in 2022 at the rate of 0.98% per year. The US also had the largest proportion of prevalent cases in 2012 (53.69%, 357,483 cases) out of all markets covered in this analysis. The forecast further shows anterior uveitis is the most common form of uveitis and non-infectious uveitis is the most common etiology among the 6MM.

This forecast provides detailed, granular, and clinically relevant segmentations of uveitis cases. The segmentations will allow for improved understanding of the disease and the ability to focus on specific subgroups within the disease. The analysis is further strengthened by the adherence to the standard clinical reporting guidelines from the International Uveitis Study Group (IUSG) and Standardization of Uveitis Nomenclature (SUN) Working Group. Using standard guidelines across the 6MM allows for meaningful comparisons across the markets and ensures these results will be relevant in reference to future studies, as the use of the guidelines are becoming more common in epidemiological research.

Scope

- This report provides an overview of the risk factors, comorbidities and the global epidemiological trends for uveitis in the six major markets (6MM: US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year forecast of incident and prevalent cases of uveitis segmented by age, sex, primary anatomical location of inflammation (anterior, intermediate, posterior, panuveitis), and by etiology (infectious, non-infectious, idiopathic). Incident cases are further segmented by course of disease (acute, recurrent, chronic) and by severity (mild, moderate, severe).
- The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global uveitis market.
- Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for uveitis therapeutics in each of the markets covered.
- Identify the number of uveitis cases in each anatomical location category and in each etiology.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Smoking increases risk of uveitis and increases complications 11
3.2.2 Juvenile idiopathic arthritis patients need regular ophthalmologic screenings 12
3.2.3 HLA-positive antigens are linked to certain types of uveitis 13
3.2.4 Uveitis is associated with various autoimmune, neurological, and infectious diseases 13
3.3 Global Trends 15
3.3.1 US 17
3.3.2 5EU 20
3.4 Forecast Methodology 22
3.4.1 Sources Used 25
3.4.2 Sources Not Used 30
3.4.3 Forecast Assumptions and Methods, Incident Cases 31
3.4.4 Forecast Assumptions and Methods, Prevalent Cases 32
3.4.5 Forecast Assumptions and Methods, Etiological and Anatomical Distribution 33
3.4.6 Forecast Assumptions and Methods, Course of Disease 36
3.4.7 Forecast Assumptions and Methods, Disease Severity 37
3.5 Epidemiological Forecast of Uveitis (2012-2022) 37
3.5.1 Incident Cases of Uveitis 37
3.5.2 Age-Specific Incident Cases of Uveitis 39
3.5.3 Sex-Specific Incident Cases 41
3.5.4 Age-Standardized Incidence Rates 42
3.5.5 Incident Cases by Anatomical Location 43
3.5.6 Incident Cases Segmented by Etiology 45
3.5.7 Course of Disease of Incident Uveitis Cases 48
3.5.8 Severity of Incident Uveitis Cases 50
3.5.9 Prevalent Cases of Uveitis 51
3.5.10 Age-Specific Prevalent Cases of Uveitis 53
3.5.11 Sex-Specific Prevalent Cases of Uveitis 54
3.5.12 Prevalent Cases by Anatomical Location 56
3.5.13 Prevalent Cases by Etiology 57
3.6 Discussion 59
3.6.1 Epidemiological Forecast Insight 59
3.6.2 Limitations of the Analysis 59
3.6.3 Strengths of the Analysis 61
4 Appendix 62
4.1 Bibliography 62
4.2 About the Authors 67
4.2.1 Epidemiologists 67
4.2.2 Reviewers 67
4.2.3 Global Director of Epidemiology and Health Policy 69
4.2.4 Global Head of Healthcare 69
4.3 About GlobalData 70
4.4 About EpiCast 70
4.5 Disclaimer 71

List of Tables

Table 1: Diseases Most Frequently Associated with Uveitis 14
Table 2: Distribution of Uveitis by Anatomical Location in Community and Referral Centers 20
Table 3: Distribution of Uveitis Cases by Anatomical Location of Inflammation, Europe 22
Table 4: IUSG/SUN Working Group Classification of Uveitis by Anatomical Location 23
Table 5: Clinical Classifications of Uveitis 23
Table 6: 6MM, Sources of Incidence and Prevalence of Uveitis in the 6MM 24
Table 7: Italy, Anatomy Classification Calculation 34
Table 8: US, Anatomical Locations of Uveitis for Incident and Prevalent Cases 36
Table 9: 6MM, Incident Cases of Uveitis, N (Column %), Select Years 2012-2022 38
Table 10: 6MM, Age-Specific Incident Cases of Uveitis, N (Row %), 2012 39
Table 11: 6MM, Sex-Specific Incident Cases of Uveitis, N (Row %), 2012 41
Table 12: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N (Row %), 2012 44
Table 13: 6MM, Incident Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 46
Table 14: 6MM, Incident Cases of Uveitis Segmented by Etiology and Anatomical Location, N, 2012 47
Table 15: 6MM, Incident Cases of Uveitis by Course of Disease, N (Row %), 2012 48
Table 16: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 50
Table 17: 6MM, Prevalent Cases of Uveitis, N (Column %), Select Years, 2012-2022 52
Table 18: 6MM, Age-Specific Prevalent Cases of Uveitis, N (Row %), 2012 53
Table 19: 6MM, Sex-Specific Prevalent Cases of Uveitis, N (Row %), 2012 55
Table 20: 6MM, Prevalent Cases of Uveitis by Anatomical Location of Inflammation, N (Row %), 2012 56
Table 21: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 57
Table 22: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Anatomical Location, 2012 58

List of Figures

Figure 1: US, Age Distribution of Study Populations Compared with the US General Population 18
Figure 2: US, Sex-Ratio of Study Populations Compared with the US General Population 19
Figure 3: 6MM, Incident Cases of Uveitis, N, 2012-2022 38
Figure 4: 6MM, Age-Specific Incident Cases of Uveitis, N, 2012 40
Figure 5: 6MM, Sex-Specific Incident Cases of Uveitis, N, 2012 42
Figure 6: 6MM, Age-Standardized Uveitis Incidence, Cases per 100,000 Population, Men and Women, 2012 43
Figure 7: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N, 2012 45
Figure 8: 6MM, Incident Cases of Uveitis by Course of Disease, N, 2012 49
Figure 9: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 51
Figure 10: 6MM, Prevalent Cases of Uveitis, N, 2012-2022 52
Figure 11: 6MM, Age-Specific Prevalent Cases of Uveitis, N, 2012 54
Figure 12: 6MM, Sex-Specific Prevalent Cases of Uveitis, N, 2012 55

Read the full report:
EpiCast Report: Uveitis - Epidemiology Forecast to 2022
http://www.reportbuyer.com/pharma_healthcare/healthcare/epicast_report_uveitis_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTred processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Did you know that you can develop for mainframes in Java? Or that the testing and deployment can be automated across mobile to mainframe? In his session at @DevOpsSummit at 20th Cloud Expo, Vaughn Marshall, Sr. Principal Product Owner at CA Technologies, will discuss and demo how increasingly teams are developing with agile methodologies using modern development environments and automating testing and deployments, mobile to mainframe.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.